Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration‐resistant prostate cancer models
Yong Luo(Capital Medical University), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center)
Cited by 50
Related Papers
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
|Oncogene|2013|879
Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastasis of lung cancer
|British Journal of Cancer|2011|173
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma
|Cancer Cell|2020|142
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancer
|Nature Communications|2020|83